Company Overview

Development Stage

About the Company

[Summary] 致力于开发在全球拥有自主知识产权的原研药物

加科思药业(1167.HK)致力于为患者提供突破性治疗方案。公司在研项目围绕KRAS、肿瘤免疫、肿瘤代谢、P53、RB、MYC六大肿瘤信号通路布局,核心项目以全球前三为目标。公司的愿景是与合作伙伴携手共进,成为全球认可的药物研发*。加科思的实验室坐落于中国北京、上海和美国波士顿,拥有诱导变构药物发现平台和iADC药物研发平台。了解更多,请访问: *

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

加科思 Financing History (4 rounds)

Manage
IPO
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Market:
  • Deal:

加科思 How Fast Is Hiring Growing? (57 open positions)

Manage
Note: How fast is hiring at 北京加科思新药研发有限公司 growing? 加科思2025: 39 openings (up 34%), 2024: 29 openings (up 12%), 2023: 26 openings (down 59%), 2022: 63 openings (down 54%), 2021: 138 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

加科思 Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Up 80%
  • 2024: Up 25%
  • 2023: Down 74%
  • 2022: Down 11%
加科思 Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at 北京加科思新药研发有限公司 growing? 加科思Master's recruitment over the years: 2025: 18 openings (up 80%), 2024: 10 openings (up 25%), 2023: 8 openings (down 74%), 2022: 31 openings (down 11%), 2021: 35 openings.

加科思 Doctoral Degree Job Demand Analysis

(More)
+200%
Growth Rate
2026 vs 2025
  • 2025: Up 400%
  • 2022: Down 55%
加科思 Doctoral Hiring by Year: 2026 — 10 more jobs than 2025
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at 北京加科思新药研发有限公司 growing? 加科思Doctorate recruitment over the years: 2026: 15 openings (up 200%), 2025: 5 openings (up 400%), 2024: 1 openings, 2022: 5 openings (down 55%), 2021: 11 openings.

加科思 R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at 北京加科思新药研发有限公司? Based on an analysis of 加科思's job postings over the past year, "生物/制药/化工/环保类" demand: 51.9%, "医疗卫生/美容保健类": 49%, "其他(研发和技术类)": 36.5%, "科研类": 35.6%, "计算机/网络/技术类": 4.8%, "电子/电器/通信技术类": 1%. For reference only.

加科思 — What Are the Salaries Like? (104 records)

Manage
salary range: 4.5K - 50K, 81.8% of roles pay ¥15-50K
Note: salary statistics are based on 104 salary records from the past year and depend on the job sample. For reference only.
How is the salary at 北京加科思新药研发有限公司?加科思81.8% of positions earn 15-50K, Fresh graduate salary: ¥21.3K。Beijing salary ranking: #915,生物/制药/化工/环保类 average salary ¥29.3K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of 加科思

(More)
Are salaries high at 北京加科思新药研发有限公司? We provide: 研究员,临床,ra,副总,数据管理,开发工程师,数据开发,培训,dm,pa,qa,助理项目经理,医学总监,医学经理,注册专员,知识产权,管理专员,管理经理,编程,高级经理. Click to view detailed salary analysis by job.

加科思 honors, qualifications & industry associations

加科思 Related Industry Tags

Job Category

  • 生物/制药/化工/环保类
    50.9% of total 50.9%
  • 医疗卫生/美容保健类
    50% of total 50%
  • 其他(研发和技术类)
    35.2% of total 35.2%
  • 科研类
    34.3% of total 34.3%

Education

  • 硕士
    50% of total 50%
  • 本科
    32.4% of total 32.4%
  • 博士
    16.7% of total 16.7%
  • 大专
    0.9% of total 0.9%

Experience

  • 3-5年
    31.5% of total 31.5%
  • 5-10年
    27.8% of total 27.8%
  • 1-3年
    23.1% of total 23.1%
  • 不限
    15.7% of total 15.7%
View Detailed Analysis

What does 北京加科思新药研发有限公司 require? Who is 加科思 hiring? 加科思 recruitment: 生物/制药/化工/环保类占比最多占50.9%,其次是医疗卫生/美容保健类占50%. What education can get in at 加科思? 硕士占比最多占50%,其次是本科占32.4%. High education required at 加科思? 硕士占50%,博士占16.7%. Work experience required at 加科思? 3-5年占比最多占31.5%,其次是5-10年占27.8%. Where are the job locations at 加科思? 北京占比最多占83.3%,其次是上海占9.3%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 29,117.7296万(元)
Legal Representative: 王印祥
Date Established:
Credit Code: 9111030235129643X7
Registered Address: 北京市北京经济技术开发区经海三路105号院8号楼

Partners & Suppliers

入驻北京亦庄生物医药园,公司提供场地及孵化服务 Source
供应商 生物医药研发客户
2019年,加科思与艾伯维就SHP2抑制剂(JAB-3068等)达成全球战略合作,加科思授予艾伯维全球开发和商业化权益,艾伯维支付首付和里程碑付款。 Source
合作客户 战略合作(License Out)

People who follow 加科思 also follow

加科思 Competitors (Similar Companies)

“Adhering to the corporate culture of science and excellence, committed”
“一家拥有70余年辉煌历史的制药企业”
医药 干细胞 药物研发 高通量筛选
疫苗 医药 生物制品 生物医药
抗肿瘤药 药物研发 大分子药物 单克隆抗体药物
“Pursuing health for all”
生物医药 原料药 化学制药 糖浆剂
制药/药业 生物医药 中成药 生产
“Buchang Pharmaceutical is a well-known high-tech health industry compa”
“Although the processing is complicated, we dare not save labor; althou”
“A technology-driven international pharmaceutical enterprise”
“To develop high-quality biologics that are accessible and affordable f”
粮油 面粉 麸皮 粮油食品
医药 原料药 药物研发 辛伐他汀
“Promoting human health”

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates